Delivery Order SPE2DB25D9363-SPE2DB25FUFSM

Award Date 4/28/25
Potential Completion Date 5/19/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $5,992.77, is for the delivery of 4,567,942,852 units of the pharmaceutical product XOLAIR 150 MG/ML AUTOINJECTORML. The contract has an ultimate completion date of May 1, 2025 and was awarded on April 10, 2025. DMS Pharmaceutical Group Inc. holds a larger...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.22 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialized pharmaceutical product, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $3,424.44 and has a period of performance through July 23, 2024. The contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialty pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 indefinite delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $6,848.88, is for the procurement of 4567192984 XOLAIR 150 MG/ML AUTOINJECTORML. The contract has an ultimate completion date of February 25, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,136.69 and a completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is to provide XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with a potential value of $3,094.80 and a completion date of February 12, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds numerous contracts and indefinite delivery vehicles (IDVs) with DLA to supply a wide range of pharmaceuticals...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,848.88 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialty pharmaceutical product, with a period of performance through August 19, 2024. This delivery order is placed against DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $2,554.02 and has a period of performance through January 28, 2025. The contract is for the delivery of XOLAIR 75 MG/0.5 ML AUTOINJECT 0.5ML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) under the DLA Medical Supply Chain program. The contract, valued at $41,093.28, is for the delivery of the pharmaceutical product Xolair 150 mg/mL auto-injector. The contract has an ultimate completion date of June 20, 2024 and was awarded on May 29, 2024. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
  • SPE2DB25D9363
    Indefinite Delivery Contract
  • SPE2DB25D9363-SPE2DB25FUFSM
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $1,712.22, is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a pharmaceutical product. The contract has an ultimate completion date of May 19, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of pharmaceutical products to federal agencies, particularly military and government healthcare facilities. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs.

Generated 7/28/25, 11:12 AM